The US Food and Drug Administration (FDA) has approved Andexxa (coagulation factor Xa [recombinant] inactivated-zhzo) to reverse the anticoagulation effects of factor Xa inhibitors when needed due to ...

Andexanet alfa (Andexxa; AstraZeneca), compared with usual care, improves hemostasis in patients who have an intracranial bleed while taking a factor Xa inhibitor, according to top-line results of ...

Among patients hospitalized with life-threatening or uncontrolled bleeding related to direct factor Xa inhibition, in-hospital and 30-day mortality vary based the type of reversal agent used, with ...

Despite considerable reductions in cardiovascular events in patients with an acute coronary syndrome (ACS) receiving dual antiplatelet therapy (DAPT), substantial residual risk persists. This unmet ...

andexxa Andexxa was initially granted accelerated approval in May 2018 for patients treated with rivaroxaban or apixaban, when reversal of anticoagulation was needed due to life-threatening or ...

Please provide your email address to receive an email when new articles are posted on . After more than 60 years of having only warfarin as an option for oral anticoagulation, several target-specific ...

Please provide your email address to receive an email when new articles are posted on . In recent years, medicine has witnessed the arrival of the direct oral anticoagulants, which include the direct ...

A total of 15 pregnant subjects on therapeutic doses of enoxaparin (1 mg/kg ±20% subcutaneously (s.c.) twice daily (b.i.d.)) were enrolled prospectively in this cross-sectional pilot project. Three ...

Treatment with the bleeding reversal agent andexanet (Andexxa) in people with acute intracerebral hemorrhage on factor Xa inhibitors led to less expansion of hematoma volume but was associated with ...

New research sheds light on the mechanism by which Rivaroxaban suppresses factor Xa and successfully attenuates atherosclerosis. New research by a team led by researchers from the Department of ...